News

Protalix BioTherapeutics said that it has made the submission in response to a request from the FDA for validation data from its upgraded manufacturing facility. The FDA is

Invida is expected to be in charge of filing and commercialising the drugs in different countries. The agreement is for an initial period of five years renewable for

Takeda’s Nesina is a selective DPP-4 inhibitor for the treatment of type 2 diabetes. PPD’s compound partnering division collaborated with Takeda to develop the product. As part of

HST Global said that with Benson’s assistance, it plans to license the ‘FIT’ protocol, as well as other pending protocols, to clinical treatment facilities in both Panama and

PPD said that the new facility will offer product and analytical development services, including method development; validation; stability, release and quality control testing; and global clinical supplies services,

PPD posted a net income of $17.2m for the first quarter 2010, or $0.14 per diluted share, compared to $45.14m, or $0.38 per diluted share, for the prior

Watson’s ANDA is for the generic equivalent of Teva’s Cenestin. The suit was filed on April 23, 2010, in the US District Court for the District of New

Shady Grove Fertility claimed that the new technology named ‘flash freezes’ increases chances of woman having her own biological children well past the age of peak fertility. Shady

Debiopharm Group said that the trial will evaluate the maximum tolerated dose and safety of Debio 0932 in patients suffering from advanced solid tumours or lymphoma. Debio 0932